Sarcomas

Alice Indini, MD, discusses the ongoing PULSAR trial examining pembrolizumab plus lenvatinib as a novel therapeutic option for patients with classic Kaposi sarcoma.

Ripretinib did not significantly improve progression-free survival over sunitinib in patients with gastrointestinal stromal tumor who previously received imatinib, missing the primary end point of the phase 3 INTRIGUE trial.

There is significant clinical, pathological, and outcome heterogeneity in myoepithelial tumors and prognoses for these tumors cannot be determined by a single pathological feature, but rather, several patient and tumor characteristics.

R. Lor Randall, MD, FACS, discusses initial considerations when treating patients with desmoid tumors.

Treatment with the next-generation anthracycline annamycin was found to result in preliminary clinical activity without dose-limiting toxicities in patients with soft tissue sarcoma lung metastases.

The use of risk stratification in children and adolescent and young adult patients with synovial sarcoma is an essential approach to appropriately tailoring local and systemic therapy and avoiding overtreatment.

Brian A. Van Tine, MD, PhD, discusses next steps with catequentinib (Anlotinib) in soft tissue sarcoma.

Patient Reported Outcomes Measurement Information System scoring indicated that preoperative and postoperative radiation therapy was associated with worse anxiety and physical function in patients with soft tissue sarcoma who had resulting wound complications compared with those who did not.

Retroperitoneal surgery for patients with sarcoma requires nuanced decision making that incorporates technical aspects of resection, as well as patient-related and tumor-related factors, according to a presentation given during the 2021 ESMO Congress.

Vimseltinib was well tolerated and demonstrated promising preliminary efficacy in patients with tenosynovial giant cell tumors whose tumors are not amendable to surgical resection, according to results from a phase 1/2 study.

Elise Nassif, MD, discusses the efficacy of early-phase clinical trials in soft tissue sarcoma.

Soft tissue sarcoma was the primary cause of death in patients over the age of 75 years, indicating that age alone should not be a prohibitive factor for treatment in older patients, according to findings from a retrospective analysis that was presented at the 2021 ESMO Congress.

Brian A. Van Tine, MD, PhD, discusses the study design, key findings, adverse events, and research beyond the APROMISS study.

Alice Indini, MD, discusses the rationale for the phase 2 PULSAR trial in classic Kaposi sarcoma.

Albiruni Ryan Abdul Razak, discusses the rationale for examining durvalumab with either olaparib or cediranib in patients with LMS, key data reported with this approach, and next steps for the phase 2 DAPPER study.

R. Lor Randall, MD, discusses survey results in detail and what the sarcoma community can do to overcome clinical trial enrollment barriers for adolescent and young adult patients.

As part of a global consensus meeting, experts from several disciplines convened to define evidence-based guidelines for the treatment of patients with primary and metastatic epithelioid hemangioendothelioma with locoregional and systemic therapies, as well as palliative care.

Albiruni Ryan Abdul Razak, MRCP, MBBCh, discusses initial findings from a phase 2 trial evaluating the utility of durvalumab in combination with olaparib or cediranib in leiomyosarcoma.

The American Society for Radiation Oncology released a new clinical guideline, which was also published in Practical Radiation Oncology, outlined recommendations and patient selection for optimal radiation dosing, sequencing, and treatment planning for patients with soft tissue sarcoma.

Amputations were found to be associated with Hispanic ethnicity and male sex in patients with neoplasms of the foot.

Brian A. Van Tine, MD, PhD, discusses outcomes with catequentinib in the treatment of patients with synovial sarcoma.

Avapritinib did not improve progression-free survival vs regorafenib in patients with unresectable or metastatic gastrointestinal stromal tumors, but the agent continues to be the most active available option for a subset of patients with PDGFRA D842V–mutant disease.

The FDA has granted an orphan drug designation to sotigalimab as a potential therapeutic option for patients with soft tissue sarcoma.

Chordoma is described as an extremely rare sarcoma that attacks the bones of the spine and base of the skull.

Brian A. Van Tine, MD, PhD, discusses the rationale to evaluate catequentinib in synovial sarcoma.